Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
70 hedge funds and large institutions have $78.2M invested in Northwest Biotherapeutics, Inc. Common stock in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 11 closing their positions.
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
80% more capital invested
Capital invested by funds: $43.5M → $78.2M (+$34.7M)
6.88% more ownership
Funds ownership: 13.89% → 20.77% (+6.9%)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
1% less funds holding
Funds holding: 71 → 70 (-1)
38% less call options, than puts
Call options by funds: $2.31M | Put options by funds: $3.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.17M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.1M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$737K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$496K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.16M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.18M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$888K |
| 4 |
MAM
Majedie Asset Management
London,
United Kingdom
|
-$757K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$390K |
NWBO Hedge Fund Activity: Q4 2014 in Review
70 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2014, worth a combined $78.2M — up 80% from $43.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NWBO positions and 11 closed out — a net gain of 1 holder — while 26 added to existing stakes and 11 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.17M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.16M sold.
- 70 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2014, down from 71 in Q3 2014.
- Funds reported $78.2M of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2014, up 80% quarter-over-quarter.
- 12 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2014 and 11 closed out, a net change of +1 holder.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2014 was Goldman Sachs, an estimated $1.17M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2014 was Franklin Resources, an estimated $5.16M sold.
Based on aggregated 13F filings for Q4 2014.